Individuals with type 2 diabetes and painful symptomatic knee osteoarthritis are less likely to achieve target glycemic ...

Background: Menstrual pain affects 45%–95% of reproductive-age females and increases the risk of other chronic pain conditions. Psychometrically sound measurement tools are essential for advancing ...

Are you a mid high-tier normie or subhuman? Explaining the guide to attractiveness that's blowing up on TikTok ...

Grand Collection showcases their reimagined 770 sneaker on the runway and in a feature skate film following an extensive rollout with a gallery in Paris Fashion Week, and an off-calendar runway show.

Meta’s deal to partially acquire the AI startup Scale, giving it 49% ownership, is certainly unusual. What Scale officially announced is that the deal values the company at over $29 billion and that ...

In people with nonspecific chronic low back pain, nonsurgical interventions like cognitive-behavioral therapy and mindfulness possibly showed small-to-moderate long-term benefits in reducing pain ...

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx (suzetrigine) in January 2025. In 2022, the Centers for Disease Control and ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine ...

Background: Severe fatigue is highly prevalent in people with inflammatory arthritis IA [1], and an important outcome clinically and in research. The BRAF MDQ and three BRAF NRS v2 (severity, ...

Joshua Pate has received speaker fees for presentations on pain and physiotherapy. He receives royalties for children's books. Dale Langford has received honoraria and research support from the ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe ...